Brighton and Sussex University Hospitals manage a significant prostate cancer patient population across the South East. For Brighton patients requiring private access to Abiraterone — whether due to NHS eligibility criteria, waiting times, or preference — generic Abiranamo provides identical clinical benefit at a fraction of branded cost.
Prostate cancer is Brighton's most commonly diagnosed male cancer. Abiranamo's mechanism of blocking CYP17A1 androgen synthesis continues to deliver meaningful survival benefit for mCRPC patients, with newer formulations also available at 500mg doses (4 x 125mg) for those preferring the food-flexible dosing schedule.
Visit medshopy.com or WhatsApp +91 82650 41513
Prostate cancer is Brighton's most commonly diagnosed male cancer. Abiranamo's mechanism of blocking CYP17A1 androgen synthesis continues to deliver meaningful survival benefit for mCRPC patients, with newer formulations also available at 500mg doses (4 x 125mg) for those preferring the food-flexible dosing schedule.
Visit medshopy.com or WhatsApp +91 82650 41513
